FINANCIAL STATEMENTS Notes to the Company Financial Statements Continued 51.
Other non-current liabilities Co-development and earnout payment agreement Cash and cash equivalents The liability mainly relates to the fair value of future payments on a co-development and earnout agreement.
Through this agreement milestone payments, dependent on successful clinical development of defined products, are received by the Group.
In return of receiving These comprise cash held by the Company and short-term bank deposits with an original maturity of three months or less.
The carrying such milestone payments, the Group agreed to pay the contracting party a certain percentage of future sales of those products.
As at amount of these assets approximates to their fair value.
31 December 2015, the liability associated with these earnout payments was adjusted to reflect the present value of the expected future cash outflows and the difference is presented as a financing cost.
Financial policies for risk management and their objectives The Directors consider that the carrying amount of other payables approximates to their fair value.
Currency risk Currency risks as defined by IFRS 7 arise on account of financial instruments being denominated in a currency that is not the functional currency and being of a monetary nature.
The following table illustrates financial assets and liabilities for the Company in different currencies: 53.
Short term debt Liabilities Assets In the previous year, short term debt mainly represented a one year syndicated bridge loan of $225 million which was entered into on 2015 2014 2015 2014 7 July 2014.
The bridge loan has been used to finance the acquisition of Bedford Laboratories note 24.
Due to subsidiaries and sister companies Non-current liabilities A sensitivity analysis based on a 1% movement in foreign exchange rates has no material impact on the Company results and Company 2015 2014 statement of changes in equity.
$m $m Hikma Pharmaceuticals LLC 100 Further details on how the Company manages the currency risk are given in Note 30.
Hikma Maple Limited 44 44 Interest rate risk Hikma Investment LLC 1 An interest rate sensitivity analysis assumes an instantaneous 100 basis point change in interest rates in all currencies from their levels Eurohealth International SARL 3 at 31 December 2015, with all other variables held constant.
Based on the composition of the Company debt and cash portfolio as at 45 147 31 December 2015, a 1% increase decrease in interest rates would result in an additional interest income of $4 million being incurred per year 2014: $1 million of interest expense incurred.
Current liabilities 2015 2014 Liquidity risk $m $m Less than Two to five Hikma Investment LLC 5 15 one year years Total West-Ward USA 31 2015 $m $m $m Hikma Farmaceutica S. A 2 Cash and cash equivalents 363 363 Thymoorgan GmbH 3 Accounts receivable 3 3 Others 1 Interest bearing loans and borrowings 20 567 587 42 15 Other payables 2 2 344 567 223 Amounts due to sister company of $42 million 2014: $15 million represent non-interest-bearing loan repayable on demand.
Less than Two to five one year years Total 55.
Long-term financial debts 2014 $m $m $m A US$500 million with a fair value of $494 million 4.25% Eurobond due April 2020 with the rating of BB Ba1.
The proceeds were used Cash and cash equivalents 148 148 to refinance existing debt and for general corporate purposes.
Accounts receivable 2 2 Interest bearing loans and borrowings 253 51 304 Other payables 1 1 104 51 155 The Company believes that, given the Groups operating cash flow during 2015, it has the ability to satisfy its liability commitments.
